Megan Abler
Family · Menasha, WINPI 1669952297
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 62.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $3,880 and has fallen 73.2% since, to $1,038 in 2025. Among family clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $64.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$7K
- Medtronic$3K
- Sanofi-aventis U.S. LLC$520
- BETA Bionics, Inc.$469
- Novo Nordisk$246
- Dexcom, Inc.$160
- plus $266 from 8 others
What the payments were for
- Consulting fees$1,20010%
- Speaking & faculty fees$5,07543%
- Travel & lodging$1,58514%
- Food & beverage$3,84333%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 47 | $7,282 |
| Medtronic | 74 | $2,760 |
| Sanofi-aventis U.S. LLC | 15 | $520 |
| BETA Bionics, Inc. | 19 | $469 |
| Novo Nordisk | 9 | $246 |
| Dexcom, Inc. | 9 | $160 |
| Insulet Corporation | 2 | $113 |
| Mannkind Corporation | 1 | $50 |
| Corcept Therapeutics | 1 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $15 |
| Amgen | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$6,438
- INPEN SMART INSULIN DELIVERY SYSTEM$1,074
- InPen$362
- SOLIQUA 100/33$233
- FreeStyle Libre$124
- Minimed 770G System$121
- Ozempic$108
- FreeStyle Libre 2$105
How this compares
$11,702 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 267 | $361,193 |
| JardianceEmpagliflozin | 268 | $269,092 |
| TrulicityDulaglutide | 151 | $203,611 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 140 | $103,248 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 57 | $94,800 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 77 | $84,171 |
| MounjaroTirzepatide | 36 | $47,933 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $44,407 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 246 | $42,943 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $28,513 |
| Humalog Kwikpen U-100Insulin Lispro | 77 | $27,931 |
| Novolog FlexpenInsulin Aspart | 88 | $21,186 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $20,174 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 50 | $17,881 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 68 | $17,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $246 | $374,707312 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $520 | $22,33834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.
Other family in Menasha
- Katlyn HansenMenasha$8K
- Sarah BertzykMenasha$5K
- Stephanie OffordMilwaukee$116K
- Laura SwobodaMenomonee Falls$111K
- Lonniel BainMadison$54K
- Linda WespGlendale$44K
- Andrea BuxtonGreen Bay$36K
- Jani CookGreen Bay$31K
- Tiffany HolleySheboygan$26K
- Kathryn SweetmanMenomonee Falls$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.